Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: A16AA05

Carbaglu(carglumic acid)

Amino Acid Metabolism, Inborn Errors;Propionic Acidemia

Marketing Authorisation Holder: Tour Hekla

EMA Authorisation: 24/01/2003

INN: carglumic acid

Indication

Carbaglu is indicated in treatment of: hyperammonaemia due to N-acetylglutamate-synthase primary deficiency; hyperammonaemia due to isovaleric acidaemia; hyperammonaemia due to methymalonic acidaemia; hyperammonaemia due to propionic acidaemia.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Carbaglu — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.